Sector News

Novartis’ global revamp to cost thousands of jobs for simpler structures: report

April 16, 2022
Life sciences

Because its goal is to have better efficiency through leaner structures, the company’s new initiative will “inevitably lead to roles being impacted,” Novartis said in a statement.
Novartis is undertaking a huge restructuring to simplify its organization, and some of its employees will feel the pain.

The company will cut thousands of jobs worldwide as part of a revamp unveiled last week, Swiss newspaper Tages-Anzeiger reports based on anonymous company sources, according to Reuters. As of the end of 2021, Novartis housed over 104,300 full-time equivalent employees.

Because the goal is to have better efficiency through leaner structures, the new initiative will “inevitably lead to roles being impacted,” a Novartis spokesperson said in a statement to Fierce Pharma. The company wouldn’t confirm whether “thousands” being impacted is in the right ballpark, saying it’s too early to give specific numbers.

Novartis rolled out the restructuring last Monday. The aim is to save at least $1 billion a year by 2024. The new structure is expected to be fully operational by the end of 2022, the spokesperson said.

Under the plan, Novartis is combining the pharmaceutical and oncology business units and is also integrating technical and customer support functions into one operations department. It’s carving out some responsibilities from the commercial and R&D teams to create a new strategy and growth function focused on optimizing the company’s pipeline.

During a presentation, Novartis CEO Vas Narasimhan noted that the company’s non-product-related expenses as a percentage of sales have remained stable over the past few years at around 29%. Among a group of 15 large pharma companies, Novartis ranked 12th for that spend percentage.

Before the reorg, Novartis’ commercial activities were managed under separate pharma and oncology organizations. They each had their own president and global marketing functions, including separations by different countries. Now, the company is dividing the commercial team into two, for the U.S. and, separately, the international market, and will have fewer layers and redundancies.

As of year-end 2021, Novartis had 41,280 employees working in sales and marketing, nearly 12,800 in operations and 4,727 in general and administration. Based on Novartis’ plan, those areas are likely where the job cuts will hit the most.

By Angus Liu


comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.